Wednesday, February 10, 2016

DiaMedica readies bridging study of DM199 protein

DiaMedica readies bridging study of DM199 protein

February 9, 2016 by · Leave a Comment 

Tweet DiaMedica (OTCQB:DMCAF; TSX-V:DMA) is preparing to begin a bridging study in the first half this year to determine the relative potency, and best dose and delivery of its lead recombinant protein, DM199. “Our near-term focus is advancing DM199 into clinical studies for the treatment of acute ischemic stroke and positioning DM199 to provide a […]

In conversation with Amir Ronen

In conversation with Amir Ronen

February 2, 2016 by · Leave a Comment 

http://www.youtube.com/watch?v=gIQEqjPh8AU&feature=youtu.be’]

Tweet As a founding member of closely-held Sensible Medical Innovations, Amir Ronen also has held the title of CEO since the company’s inception in late 2007. Mr. Ronen has over 15 years of experience in senior management roles at leading global companies, including VP of marketing and business development at M-Systems, which was acquired by […]

In conversation with Dr. Alan Schwebel

In conversation with Dr. Alan Schwebel

January 26, 2016 by · Leave a Comment 

Tweet As president and CEO of BioView (TASE:BIOV), Dr. Alan Schwebel has led the company, a world leader in automated fluorescence in situ hybridization (FISH) cell imaging and analysis, since 2009. Dr. Schwebel, who has more than 30 years of experience in senior management positions in leading medical device and medical diagnostic companies, joined BioView […]

EyeGate developing non-invasive ophthalmic treatments

EyeGate developing non-invasive ophthalmic treatments

January 19, 2016 by · Leave a Comment 

Tweet EyeGate Pharmaceuticals (NASDAQ:EYEG) is developing a non-invasive drug delivery platform that uses an electrical process, known as iontophoresis, to deliver a corticosteroid to the front-and back-of-the-eye for the treatment of ophthalmic conditions, such as anterior uveitis, macular edema and post-cataract surgery inflammation. “Our EyeGate II Delivery System addresses two of the most prevalent issues in […]

Fibrocell translating personalized biologics into medical breakthroughs

Fibrocell translating personalized biologics into medical breakthroughs

January 12, 2016 by · Leave a Comment 

Tweet Fibrocell Science (NASDAQ:FCSC) is developing a pipeline of cell and gene therapies for localized treatment of connective tissue and joint diseases using autologous fibroblasts to deliver a targeted gene. “Our personalized biologics approach represents a dynamic new dimension to the field of cell therapy and regenerative medicine, aimed at treating the underlying cause of […]

BioSight developing non-toxic drug against leukemia

BioSight developing non-toxic drug against leukemia

January 5, 2016 by · Leave a Comment 

Tweet Closely-held BioSight is in clinical development with its lead chemotherapy drug, Astarabine, as a non-toxic treatment for hematologic malignancies, including acute myeloid leukemia (AML). “Treatment and outcomes in AML patients have not changed much in decades,” CEO, Dr. Ruth Ben Yakar, says in an interview with BioTuesdays.com, pointing to high toxicity and treatment limitations […]

Season’s Greetings (and JPM 2016)

Season’s Greetings (and JPM 2016)

December 22, 2015 by · Leave a Comment 

Tweet Wow, what an interesting year 2015 has turned out to be! Everyone at BioTuesdays would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and friends, we will be back in full swing with our next Tuesday Feature on January 5. On another […]

In conversation with Kevin Smith

In conversation with Kevin Smith

December 15, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=aABLBoCzkVg’]

Tweet As the newly appointed chief commercial officer of closely-held Sensium Healthcare, a pioneer in wireless monitoring of patient vital signs, Kevin Smith is in charge of developing and executing the company’s global commercial strategy. He also controls partnering with U.S. hospitals and medical universities and building clinical evidence for SensiumVitals, the first early warning […]

BioLight Life Sciences focusing on ophthalmic portfolio

BioLight Life Sciences focusing on ophthalmic portfolio

December 8, 2015 by · Leave a Comment 

Tweet BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) is now defining itself as an ophthalmology company after spending several years assembling a cluster of investments in the sector as well as in cancer diagnostics. “We believe there is a huge value potential from the ophthalmic therapeutics and diagnostics we have gathered,” CEO, Suzana Nahum Zilberberg, says […]

Oramed sees value creating events through 2016

Oramed sees value creating events through 2016

December 1, 2015 by · Leave a Comment 

Tweet Oramed Pharmaceuticals’ (NASDAQ:ORMP) oral insulin development program has multiple value-creating events in the works through 2016. They include completion of an ongoing Phase 2b FDA multi-site study for oral insulin (ORMD-0801) in Type 2 diabetes, completion of a Phase 2a FDA study and initiation of a Phase 2b multi-site study in Type 1 diabetes, […]

Next Page »

Email Newsletters with Constant Contact
Google+